ZHEJIANG STARRY PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.87 CNY | -0.54% |
|
+2.39% | -8.59% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 2.77B 384M | Sales 2025 * | 3.34B 463M | Capitalization | 4.41B 611M |
|---|---|---|---|---|---|
| Net income 2024 * | 195M 27.02M | Net income 2025 * | 382M 52.93M | EV / Sales 2024 * | 1.59 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.32 x |
| P/E ratio 2024 * |
22.6
x | P/E ratio 2025 * |
11.5
x | Employees | 1,842 |
| Yield 2024 * |
1.94% | Yield 2025 * |
2.72% | Free-Float | 62.03% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.54% | ||
| 1 week | +2.39% | ||
| Current month | +2.39% | ||
| 1 month | -1.68% | ||
| 3 months | +53.21% | ||
| 6 months | -19.01% | ||
| Current year | -8.59% |
1 week
12.62
13.10
1 month
10.6013.10
Current year
7.8614.30
1 year
7.8617.46
3 years
7.8657.26
5 years
7.8670.36
10 years
6.1370.36
| Managers | Title | Age | Since |
|---|---|---|---|
Wei Yi Shen
CEO | Chief Executive Officer | 44 | 09-08-31 |
Jun Feng Guo
DFI | Director of Finance/CFO | 39 | 22-12-25 |
Jian Hu
CHM | Chairman | 45 | 10-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hong Fei Zhang
BRD | Director/Board Member | 45 | 23-05-08 |
Mei Ying Mao
BRD | Director/Board Member | 61 | 23-05-08 |
Jin Sheng Hu
BRD | Director/Board Member | 69 | 03-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 0 M€ | +3.53% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-07 | 12.87 | -0.54% | 5,178,431 |
| 24-05-06 | 12.94 | +2.94% | 7,505,546 |
| 24-04-30 | 12.57 | +1.53% | 7,588,420 |
End-of-day quote Shanghai S.E., May 06, 2024
More quotes
Zhejiang Starry Pharmaceutical Co., Ltd. is principally engaged in the research and development (R&D), production and sales of X-ray contrast medium, quinolone antimicrobial agents and other drugs' pharmaceutical raw materials and intermediates. The X-ray contrast medium's major product is iohexol active pharmaceutical ingredient. Quinolone antimicrobial agents' major products are levofloxacin hydrochloride active pharmaceutical ingredient and levofloxacin hemihydrates active pharmaceutical ingredient.
Sector
Pharmaceuticals
Calendar
2024-05-21
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
12.87
CNY
Average target price
17.54
CNY
Spread / Average Target
+36.29%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -8.59% | 615M | |
| +33.43% | 690B | |
| +26.43% | 546B | |
| -5.12% | 358B | |
| +19.59% | 323B | |
| +4.89% | 287B | |
| +14.32% | 235B | |
| +5.79% | 199B | |
| -9.49% | 195B | |
| +4.26% | 161B |
- Stock Market
- Equities
- 603520 Stock